Sheldon Chris (Chris Sheldon)

Sheldon Chris (Chris Sheldon)

Biography

2022: AstraZeneca banned from GSK via court

On September 1, 2022, it became known that AstraZeneca managed to stop the former top manager from moving to work for rival GSK after the High Court in London granted an injunction during a trial between the two largest pharmaceutical companies in the UK.

Chris Sheldon, after informing AstraZeneca of his intention to move in April 2022, left the company in August 2022 after holding several senior roles, was due to begin work at GSK on September 1, 2022, responsible for the development of all the group's therapeutic areas.

AstraZeneca through the court forbade the ex-leader to move to GSK

In July 2022, AstraZeneca took Sheldon to court, arguing that by starting work at GSK before February 2023, he would breach a non-competition agreement that was supposed to be in place for six months. Shildon denies all charges and any wrongdoing. At the same time, it is known that he received shares worth £644,553 in exchange for signing an agreement.

The case is due to go to court in October 2022, but in 31 August 2022 AstraZeneca applied to the High Court for an urgent injunction to prevent Sheldon, who was head of investor affairs at AstraZeneca and held a senior position in the company's cancer business, from starting work on 1 September.

Daniel Oudkirk, who represents AstraZeneca, told the High Court that the pharmaceutical group was "likely to suffer irreparable damage" if Sheldon could start work at GSK before the trial began in October.

Шаблон:Quote 'Obviously AstraZeneca has a legitimate business interest in protecting its confidential information,' Oudkirk said, adding that Sheldon had knowledge of the group's existing drugs, drug development, and business development and commercial strategy. James Laddy, who represents Sheldon, said there was no reason to ban the former AstraZeneca executive from doing work unrelated to either of the two positions he held during his last 12 months at AstraZeneca.

Шаблон:Quote 'Sheldon had an impeccable track record and was never supposed to have been interested in or taken confidential information for use at GSK, "Laddy said. Judge Heather Williams ruled that the most fair and correct decision would be to stay the case pending trial and grant an injunction.

{{quote 'Despite the fact that this interim decision upset us, we are convinced of the strength of Sheldon's position and believe that he will take his new position at GSK after the main hearing in October, GSK said. ^[1] }}

Notes